pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Apixaban · news · pharmadog
← back to Apixaban
News mentioning Apixaban
16
stories
10d
BMS picks Texas for new $2.3B manufacturing campus
biospace
15d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
15d
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
15d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
biospace
16d
Pfizer expands multibillion-dollar cost-cutting plan
biopharma dive
16d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
16d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
17d
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
20d
Trump administration tries again to institute rebates in 340B
biopharma dive
20d
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
biopharma dive
21d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
21d
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
fiercebiotech
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
